Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

Summit now has quality-of-life data for its ridinilazole to treat Clostridium difficile infections showing benefits over SOC that could help HTAs such as NICE as they develop new value assessment frameworks to capture the benefits of antibiotics.

On Thursday, Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) reported patient-reported outcomes data from the Phase II CoDIFy trial that showed that ridinilazole had a statistically

Read the full 604 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers